Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
207 hedge funds and large institutions have $3.62B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 43 closing their positions.
37% more call options, than puts
Call options by funds: $71.1M | Put options by funds: $51.8M
17% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 63
11% more capital invested
Capital invested by funds: $3.27B → $3.62B (+$350M)
3% less funds holding
Funds holding: 214 → 207 (-7)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
12% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$110M |
| 2 |
Blackstone Inc
New York
|
+$42.4M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$22M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$78.5M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$23.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.8M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.3M |
RETA Hedge Fund Activity: Q2 2020 in Review
207 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2020, worth a combined $3.62B — up 11% from $3.27B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of RETA and 38 opened new positions — a net loss of 5 holders — while 63 trimmed existing stakes and 74 added.
The largest buyer was Wellington Management Group, adding an estimated $110M. The largest seller was BlackRock, cutting an estimated $78.5M.
- 207 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2020, down from 214 in Q1 2020.
- Funds reported $3.62B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2020, up 11% quarter-over-quarter.
- 38 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2020 and 43 closed out, a net change of -5 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2020 was Wellington Management Group, an estimated $110M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2020 was BlackRock, an estimated $78.5M sold.
Based on aggregated 13F filings for Q2 2020.